Form 8-K CYTRX CORP For: Apr 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
Go back to Form 8-K CYTRX CORP For: Apr 30
May 4, 2015 9:04 AM EDT
CytRx (NASDAQ: CYTR) announced an interim analysis from its two ongoing phase 1b aldoxorubicin combination studies pairing aldoxorubicin with either gemcitabine or ifosfamide. Both studies combine standard doses of gemcitabine or ifosfamide with escalating doses of aldoxorubicin. The combinations appear to be well tolerated, and even at the lowest dose level of aldoxorubicin (170 mg/m2), impressive tumor responses have been observed so far in patients with bone cancer (osteosarcoma) and a variety of soft tissue sarcomas. As such, aldoxorubicin has the potential when used in combination with other cancer agents to become an important new... More
May 1, 2015 6:06 AM EDT
CytRx (NASDAQ: CYTR) reported Q1 EPS of $0.31, $0.52 better than the analyst estimate of ($0.21).
CytRx recently appointed two new independent members to its Board of Directors. Effective April 30, 2015, Eric J. Selter, J.D. joined the Board and will serve as... More
